14,913 Shares in Abbott Laboratories $ABT Bought by Atlas Capital Advisors Inc.

Atlas Capital Advisors Inc. purchased a new position in Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 14,913 shares of the healthcare product maker’s stock, valued at approximately $1,868,000.

A number of other large investors have also modified their holdings of ABT. Norges Bank purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth $2,938,892,000. Invesco Ltd. grew its holdings in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Ninety One UK Ltd purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth $336,815,000. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of Abbott Laboratories by 122.0% during the fourth quarter. Stifel Financial Corp now owns 3,947,686 shares of the healthcare product maker’s stock worth $494,610,000 after buying an additional 2,169,184 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 2.0%

Shares of ABT opened at $87.89 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The firm has a 50-day moving average price of $91.46 and a 200 day moving average price of $107.98. The firm has a market capitalization of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the prior year, the firm posted $1.09 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABT. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a report on Wednesday, April 22nd. Piper Sandler dropped their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Oppenheimer dropped their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. BofA dropped their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday. Finally, Stifel Nicolaus dropped their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.38.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.